<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05005884</url>
  </required_header>
  <id_info>
    <org_study_id>1401</org_study_id>
    <nct_id>NCT05005884</nct_id>
  </id_info>
  <brief_title>Possible Effects of Supplement Therapy With Oral Phenolics on Cluster of Differentiation 163 (CD-163) Biomarker of Patients With Age-related Macular Degeneration</brief_title>
  <official_title>Evaluation of the Possible Effects of Supplement Therapy With Oral Phenolics on Plasma CD-163 Biomarker in Patients With Different Subtypes of Age-related Macular Degeneration; a Double-blind Placebo Controlled Prospective Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Harvard Medical School (HMS and HSDM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swiss Eye Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this multi-center study, possible effects of supplement treatment with oral phenolics on&#xD;
      plasma CD-163 and progression of dry and wet age-related macular degeneration (AMD) via&#xD;
      evaluating the CD163 before and after the prescription of this drug will be evaluated in&#xD;
      patients with dry type AMD and Neo vascular age-related macular degeneration (nAMD).&#xD;
&#xD;
      Both AMD subgroups will be recruited. In terms of evaluation of the effects of phenolics (500&#xD;
      mg caplets/day) on AMD progression, patients will be randomized and divided into 2 subgroups&#xD;
      i.e. (i) receiving phenolics supplementation; and, (ii) receiving placebo for 1 month. The&#xD;
      phenolics/placebo caplets will resemble completely and be encoded at origin; Neither the&#xD;
      participants nor the researchers will be informed about the codes until the end of the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 28, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of Plasma CD-163</measure>
    <time_frame>1 month</time_frame>
    <description>Blood sampling</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decimal acuity of vision</measure>
    <time_frame>1 month</time_frame>
    <description>Snellen chart</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Age Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>oral phenolics intake</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prescription of oral phenolics 250 mg two times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo caplet intake</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Prescription of oral phenolics 250 mg two times daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral intake of medication</intervention_name>
    <description>Prescription of oral phenolics 250 mg two times daily</description>
    <arm_group_label>oral phenolics intake</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Prescription of oral phenolics 250 mg two times daily</description>
    <arm_group_label>placebo caplet intake</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of intermediate to late AMD (dry AMD and nAMD )&#xD;
&#xD;
          -  Age-matched controls without any sign of AMD&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Systemic disease or other eye-related diseases (diabetes, immunologic or inflammatory,&#xD;
             active or chronic infectious disease, active malignancy, uveitis, retinal vascular&#xD;
             occlusive disease, glaucoma)&#xD;
&#xD;
          -  Systemic therapy with corticosteroids or biological drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ophthalmic Research Center</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 1, 2021</study_first_submitted>
  <study_first_submitted_qc>August 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2021</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shahid Beheshti University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Zahra Rabbani Khah</investigator_full_name>
    <investigator_title>Head of ophthalmic research center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

